START Midwest

Midwest

Grand Rapids, MI

Sorting 1 by

Not yet accepting

S227928

Phase 1/2 Clinical Trial of S227928, an Anti-CD74 Antibody-Drug Conjugate Targeting MCL-1, as a Single Agent and in Combination With Venetoclax in Patients With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML)
  • Antibody Drug Conjugate (ADC)
  • MCL-1 Inhibitor
  • CD74
  • Phase 1/2